Last update 01 Nov 2024

Vesicular nucleotide transporter

Last update 01 Nov 2024

Basic Info

Synonyms-

Introduction-

Drugs associated with Vesicular nucleotide transporter

Clodronate Disodium

Target

Vesicular nucleotide transporter

Mechanism

Vesicular nucleotide transporter inhibitors

Active Org.

Guangzhou Baiyunshan Ming Xing Pharmaceutical Co., Ltd. [+3]

Originator Org.-

Active Indication

Bone metastases [+3]

Inactive Indication

Osteoarthritis

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date01 Jan 1986

Clinical Trials associated with Vesicular nucleotide transporter

NCT06263517 / RecruitingPhase 2/3

Adaptative, Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled, Clinical Trial, on the Efficacy and Tolerability of Different Escalating Doses of Intra-articular Clodronate in Patients With Painful Knee Osteoarthritis

The goal of this clinical trial is to to clarify which is the best dose of administration, to select a dose and to confirm the therapeutic efficacy of clodronate in patients with painful knee osteoarthritis (OA). The clinical trial will be divided in two parts.
The main questions it aims to answer are:
in Phase II, to assess the safety and tolerability of different escalating doses of intra articular (IA) clodronate
in Phase II, to set a defined therapeutic dose (DTD) to be used in Phase III
in Phase III, to assess the safety and tolerability of different escalating doses of IA clodronate to confirm and extensively evaluate the therapeutic efficacy and safety of the clodronate DTD in patients with knee OA

Start Date12 Oct 2023

Sponsor / Collaborator

Società Prodotti Antibiotici SpA

EUCTR2021-003124-33-IT / Unknown statusPhase 2/3

Adaptative, multicenter, randomized, double-blind, parallel-group, placebo controlled, clinical trial, on the efficacy and tolerability of different escalating doses of intra-articular clodronate in patients with painful knee osteoarthritis - SPA-S-899-01-21

Start Date15 May 2023

Sponsor / Collaborator-

ChiCTR1900024141 / RecruitingEarly Phase 1IIT

Phase II clinical study for skull base osteoradionecrosis by treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO)

Start Date01 Jul 2019

Sponsor / Collaborator

Jiangxi Provincial Cancer Hospital

100 Clinical Results associated with Vesicular nucleotide transporter

100 Translational Medicine associated with Vesicular nucleotide transporter

0 Patents (Medical) associated with Vesicular nucleotide transporter

131

Literatures (Medical) associated with Vesicular nucleotide transporter

01 Apr 2024·Purinergic Signalling

María Teresa Miras Portugal: a pioneer for vesicular nucleotide storage

Review

Author: Nomura, Masatoshi ; Moriyama, Yoshinori ; Hasuzawa, Nao

Chromaffin granules are secretory granules present in adrenal medulla chromaffin cells. They contain high contents of catecholamines and nucleotides and have been regarded as a model system for the study of vesicular transmitter uptake and release. In 1988, Dr. María Teresa Miras Portugal, when studying catecholamine biosynthesis, detected a novel group of nucleotides, the diadenosine polyphosphates, in the adrenal chromaffin granules. Based on this finding, she unraveled the existence of diadenosine polyphosphate-mediated chemical transmission, leading to a paradigm shift in the field of purinergic signaling. She is also a pioneer in the studies on vesicular nucleotide storage. First, María Teresa and her group characterized nucleotide transport in chromaffin granules and synaptic vesicles using fluorescent nucleotide derivatives such as 1, N6-ethenoadenosine triphosphates. Then, they revealed the presence of a hypothetical vesicular nucleotide transporter with unique properties in terms of substrate specificity. In this article, we will describe her contributions to vesicular nucleotide storage and the foundations she laid for future studies.

01 Jan 2024·Journal of Histochemistry & Cytochemistry

ADP-mediated Modulation of Intracellular Calcium Responses in Chromaffin Cells: The Role of Ectonucleoside Triphosphate Diphosphohydrolase 2 on Rat Adrenal Medulla Function

Article

Author: Sato, Kenichi ; Maesawa, Satsuki ; Sakanoue, Wakana ; Yamamoto, Yoshio ; Yokoyama, Takuya ; Hirakawa, Masato ; Saino, Tomoyuki ; Shiraishi, Hirohisa

The present study investigated the localization and the adenosine 5′-triphosphate (ATP)-degrading function of the plasma membrane-bound ecto-nucleotidase, ectonucleoside triphosphate diphosphohydrolase 2 (NTPDase2), in the rat adrenal medulla. The effect of ATP degradation product, adenosine 5′-diphosphate (ADP), on carbachol (CCh)-induced intracellular Ca2+ ([Ca2+]i) responses in adrenal chromaffin cells was examined using calcium imaging. NTPDase2-immunoreactive cells were distributed between chromaffin cells. NTPDase2-immunoreactive cells were immunoreactive for glial fibrillary acidic protein and S100B, suggesting that they were sustentacular cells. NTPDase2-immunoreactive cells surrounded chromaffin cells immunoreactive for vesicular nucleotide transporter and P2Y12 ADP-selective purinoceptors. In ATP bioluminescence assays using adrenal medullary slices, ATP was rapidly degraded and its degradation was attenuated by the NTPDase inhibitors sodium polyoxotungstate (POM-1) and 6- N, N-diethyl-d-β,γ-dibromomethylene ATP (ARL67156). ADP inhibited CCh-induced [Ca2+]i increases of chromaffin cells in adrenal medullary slices. The inhibition of CCh-induced [Ca2+]i increases by ADP was blocked by the P2Y12 purinoceptor antagonist AZD1283. CCh-induced [Ca2+]i increases were also inhibited by the P2Y1, P2Y12, and P2Y13 purinoceptor agonist 2-methylthioadenosine diphosphate trisodium (2MeSADP), in combination with the P2Y1 purinoceptor antagonist MRS2179. These results suggest that sustentacular cells express NTPDase2 to degrade ATP released from adrenal chromaffin cells, and ADP modulates the excitability of chromaffin cells via P2Y12 purinoceptors to regulate catecholamine release during preganglionic sympathetic stimuli. (J Histochem Cytochem 72: 41–60, 2024)

01 Jan 2024·Protein & Peptide Letters

LINC01836 Promotes Colorectal Cancer Progression and Functions as ceRNA to Target SLC17A9 by Sponging miR-1226-3p

Article

Author: Ni, Hao ; Yu, Yue ; Kuang, Yuting ; Xu, Zhihua ; Sun, Wei

Background:Increasing evidence proves that long non-coding RNAs (lncRNAs) play a key role in the occurrence and development of colorectal cancer. However, the function and molecular mechanism of LINC01836 in CRC are still unknown.Methods:The differentially expressed lncRNAs in colorectal cancer were obtained from the RNA sequencing data. The effects of LINC01836 on colorectal cancer cells were tested in in vitro experiments. The mechanism of LINC01836 action was investigated through western blot, RNA immunoprecipitation assay and luciferase reporter assay. Moreover, the xenograft mouse model was conducted to examine the effects of LINC01836 in vivo.Results:In this study, we showed that LINC01836 was significantly elevated in colorectal cancer tissues and cells. Elevated LINC01836 expression significantly correlated with larger tumor size, positive lymph node metastasis, distant metastasis, advanced tumor-node-metastasis (TNM) stage, and poor prognosis. Furthermore, decreased expression of LINC01836 repressed proliferation, migration, and invasion in vitro and vivo, and high LINC01836 expression displayed the opposite effect. Further analysis revealed that LINC01836 could regulate the expression of SLC17A9 by competing with miR-‐1226-3p. Furthermore, down-regulation of LINC01836 or increased expression of miR-‐1226-3p markedly reversed the effects of SLC17A9 overexpression on colorectal cancer cells.Conclusion:This study showed that LINC01836 regulated the expression of SLC17A9 through sponge miR-1226-3p by acting as a competitive endogenous RNA (ceRNA), promoted the progression of colorectal cancer, and suggested a new prognostic biomarker and potential cancer treatment target for colorectal cancer.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Vesicular nucleotide transporter

Basic Info

Related

Analysis